Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators

Abstract

Aim: To develop a comprehensive item library of patient-reported, immunotherapy-related adverse events (irAEs) that draws from and expands on the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System.

Methods: Literature review and iterative expert input. Based on a literature review of irAEs, we developed a framework of immunotherapy classes and their associated symptoms. Clinical experts then reviewed iterations of symptom summaries and item maps linked to the immunotherapy framework. Experts provided content review and feedback was shared across experts until consensus was reached. The iterative process facilitated creation of a Primary Symptom List associated with immune checkpoint modulators (ICMs), drawn from the larger set of symptoms. Existing FACIT items were mapped to the symptom list, and new items were written as needed to create the item library.

Results: The full item library of irAEs is comprised of 239 items, covering 142 unique symptoms across 75 inflammatory reactions/immune conditions. A subset of 66 items comprises a Primary Symptom List considered most common/relevant to ICM treatment. This includes gastrointestinal, skin, pulmonary, neurologic, musculoskeletal, and multiple miscellaneous and constitutional symptoms.

Conclusion: The FACIT Immunotherapy Item Library is a compilation of 239 self-report items that capture the wide range of AEs experienced by people receiving immune treatments. A subset of 66 items comprises a Primary Symptom List meant for ICM therapy. Use of items selected from this library is encouraged in clinical research and clinical practice evaluation.

Keywords

Immunotherapy / immune checkpoint modulators / quality of life / immune-related adverse events / patient reported outcomes / cancer / oncology

References

[1] Hellmann MD,Pluzanski A,Otterson GA.Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden..N Engl J Med2018;378:2093-104

[2] Le DT,Wang H,Kemberling H.PD-1 blockade in tumors with mismatch-repair deficiency..N Engl J Med2015;372:2509-20 PMCID:PMC4481136

[3] Reck M,Robinson AG,Csoszi T.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer..N Engl J Med2016;375:1823-33

[4] Brahmer JR,Schneider BJ,Brassil KJ.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline..J Clin Oncol2018;36:1714-68 PMCID:PMC6481621

[5] Ventola CL.Cancer immunotherapy, part 2: efficacy, safety, and other clinical considerations..P T2017;42:452-63 PMCID:PMC5481296

[6] Carretero-Gonzalez A,Ghanem I,Castellano D.Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials..Oncotarget2018;9:8706-15 PMCID:PMC5823578

[7] Temel JS,Sullivan RJ.Keeping expectations in check with immune checkpoint inhibitors..J Clin Oncol2018;36:1654-7

[8] Fox J,Bennett F.An outreach telephone program for advanced melanoma supportive care: acceptability and feasibility..Eur J Oncol Nurs2019;42:110-5

[9] Haanen J,Robert C,Peters S.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up..Ann Oncol2017;28:iv119-42

[10] Puzanov I,Abdallah K,Brogdon C.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group..J Immunother Cancer2017;5:95 PMCID:PMC5697162

[11] Chen TW,Bedard PL,Hansen AR.A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors..Ann Oncol2015;26:1824-9

[12] Kottschade LA.Incidence and management of immune-related adverse events in patients undergoing treatment with immune checkpoint inhibitors..Curr Oncol Rep2018;20:24

[13] Michot JM,Champiat S,Carbonnel F.Immune-related adverse events with immune checkpoint blockade: a comprehensive review..Eur J Cancer2016;54:139-48

[14] Postow MA,Hellmann MD.Immune-related adverse events associated with immune checkpoint blockade..N Engl J Med2018;378:158-68

[15] Suarez-Almazor ME,Abdel-Wahab N.Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer..Arthritis Rheumatol2017;69:687-99

[16] Anagnostou V,Hansen AR,Verde F.Immuno-oncology trial endpoints: capturing clinically meaningful activity..Clin Cancer Res2017;23:4959-69 PMCID:PMC5735844

[17] US Department of Health and Human Services - FDA Center for Drug Evaluation and ResearchGuidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance..Health Qual Life Outcomes2006;4:79 PMCID:PMC1629006

[18] Cella D.Re-personalizing precision medicine: is there a role for patient-reported outcomes?.J Community Supp Oncol2015;13:275-7

[19] Cella D,Escudier B,George S.Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial..Lancet Oncol2019;20:297-310 PMCID:PMC6701190

[20] Cella D,Kudlac A,Oukessou A.Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study..Ann Hematol2018;97:2455-63 PMCID:PMC6208683

[21] Bouchard LC,Gondek K.Cancer symptom response as an oncology clinical trial end point..Expert Rev Qual Life Cancer Care2018;3:35-46 PMCID:PMC6476191

[22] Cella D,Tannir NM,Donskov F.Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial..J Clin Oncol2018;36:757-64 PMCID:PMC6804841

[23] Basch E,Barz A,Kris MG.Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy..J Clin Oncol2007;25:5374-80

[24] Atkinson TM,Heon N,Shaw M.Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting..J Cancer Res Clin Oncol2017;143:735-43 PMCID:PMC5354957

[25] Basch E,Heller G,Sit L.Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes..J Natl Cancer Inst2009;101:1624-32 PMCID:PMC2786917

[26] Cella D,Jensen SE,Nowinski CJ.Patient-reported outcomes in performance measurement.2015;Research Triangle Park (NC)RTI Press1

[27] Jim HS.American society of clinical oncology value framework: importance of accurate toxicity data..J Clin Oncol2017;35:1133-4

[28] Webster K,Yost K.The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation..Health Qual Life Outcomes2003;1:79 PMCID:PMC317391

[29] Aaronson NK,Bergman B,Cull A.The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology..J Natl Cancer Inst1993;85:365-76

[30] Cella D,Stone A,Reeve B.The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008..J Clin Epidemiol2010;63:1179-94 PMCID:PMC2965562

[31] Basch E,Mitchell SA,Minasian LM.Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)..J Natl Cancer Inst2014;106: PMCID:PMC4200059

[32] Hall ET,Dickerson J,Wong HN.Patient-reported outcomes for cancer patients receiving checkpoint inhibitors: opportunities for palliative care-a systematic review..J Pain Symptom Manage2019;58:137-56.e1

[33] King-Kallimanis BL,Roydhouse JK,Theoret MR.Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions..Clin Trials2019;16:322-6

[34] Rand Corporation. Delphi Method. Available from: http://www.rand.org/topics/delphi-method.html [Last accessed on 4 Mar 2020]

[35] Keeney S,Mckenna H.The delphi technique in nursing and health research.2010;Hoboken, New JerseyWiley-Blackwell

[36] Functional assessment of chronic illness therapy (FACIT) searchable library and custom form developer (Build-a-PRO). Available from: https://wizard.facit.org/ [Last accessed on 4 Mar 2020]

[37] Bonomi AE,Hahn EA,Sperner-Unterweger B.Multilingual translation of the functional assessment of cancer therapy (FACT) quality of life measurement system..Qual Life Res1996;5:309-20

[38] Eremenco SL,Arnold BJ.A comprehensive method for the translation and cross-cultural validation of health status questionnaires..Eval Health Prof2005;28:212-32

[39] Thompson JA,Brahmer J,Armand P.Management of immunotherapy-related toxicities, version 1.2019..J Natl Compr Canc Netw2019;17:255-89

[40] Abdel-Wahab N,Lopez-Olivo MA.Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review..Ann Intern Med2018;168:121-30

[41] Bajwa R,Khan T,Paul A.Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study..J Clin Med Res2019;11:225-36 PMCID:PMC6436564

[42] Delanoy N,Comont T,Lazarovici J.Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study..Lancet Haematol2019;6:e48-e57

[43] Hryniewicki AT,Shatsky RA.Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physicians..J Emerg Med2018;55:489-502

[44] Khan S.Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review..Semin Cancer Biol2019;Epub ahead of print. doi: 10.1016/j.semcancer.2019.06.012

[45] Myers G.Immune-related adverse events of immune checkpoint inhibitors: a brief review..Curr Oncol2018;25:342-7 PMCID:PMC6209551

[46] Teufel A,Hartel N,Ebert MP.Management of immune related adverse events induced by immune checkpoint inhibition..Cancer Lett2019;456:80-7

[47] Calabrese LH,Cappelli LC.Rheumatic immune-related adverse events from cancer immunotherapy..Nat Rev Rheumatol2018;14:569-79

[48] Cappelli LC,Baer AN,Manno RL.Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab..Ann Rheum Dis2017;76:43-50 PMCID:PMC5333990

[49] Sibaud V.Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy..Am J Clin Dermatol2018;19:345-61

[50] Tan MH,Mizokami-Stout K,MacEachern MP.Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports..Clin Diabetes Endocrinol2019;5:1 PMCID:PMC6343255

[51] Girotra M,Farooki A,Min L.The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management..JNCI Cancer Spectr2018;2:pky021 PMCID:PMC6054022

[52] Lacouture M.Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails..Am J Clin Dermatol2018;19:31-9 PMCID:PMC6244569

[53] Reddy HG,Tai AW.Immune checkpoint inhibitor-associated colitis and hepatitis..Clin Transl Gastroenterol2018;9:180 PMCID:PMC6143593

[54] Benfaremo D,Luchetti MM.Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature..Curr Drug Saf2018;13:150-64 PMCID:PMC6198478

[55] Wang ZH.Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors..Chronic Dis Transl Med2018;4:1-7 PMCID:PMC5938241

[56] Delaunay M,Lusque A,Gounant V.Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients..Eur Respir J2017;50:pii: 1700050

[57] Mayo Clinic Website. Available from: https://www.mayoclinic.org/ [Last accessed on 4 Mar 2020]

[58] Hansen AR,McKillop C,Bedard PL.Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): a scale to measure quality of life in cancer patients treated with ICMs..IASS J2020;Epub ahead of print. doi: 10.1002/cncr.32692

[59] Shaw SS,Eisel S,LeDuc D.Patient reported toxicities: development and validation of patient-reported symptom measure for lung cancer patients receiving immunotherapy..J Clin Oncol2019;37:93